TOWA PHARMACEUTICAL CO.,LTD., First Half Ordinary Profit Revised Upward to an Unexpected 1% Increase, Full Year also Increased

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Tue Nov 5, 2024 3:30 pm JST Revision

4553 TOWA PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Guidance Update Report

TOWA PHARMACEUTICAL CO.,LTD. <4553> [TSE-P] announced a performance revision after the market closed on November 5th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2025 (April to September) has been revised upward by 51.5%, from the previous forecast of 6.8 billion yen to 10.3 billion yen (compared to 10.2 billion yen in the same period of the previous year), turning to a 0.7% increase in the consolidated ordinary profit outlook.

Following the strong performance in the first half, the full-year consolidated ordinary profit has been revised upward by 18.2%, from the previous forecast of 19.2 billion yen to 22.7 billion yen (compared to 24.4 billion yen in the previous period), and the declining rate is expected to decrease from 21.6% to 7.3%.

Kabutan News

Guidance Update

First Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024 Prev	122,800	6,800	6,800	4,100	83.3	30	Aug 8, 2024	J-GAAP
Apr - Sep, 2024 New	123,400	10,500	10,300	6,500	132.0	30	Nov 5, 2024	J-GAAP
Revision Rate	+0.5%	+54.4%	+51.5%	+58.5%	+58.5%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	261,500	19,600	19,200	12,600	256.0	60	Aug 8, 2024	J-GAAP
Mar, 2025 New	262,100	23,300	22,700	15,000	304.7	60	Nov 5, 2024	J-GAAP
Revision Rate	+0.2%	+18.9%	+18.2%	+19.0%	+19.0%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2023	107,396	7,003	10,233	6,953	141.3	30	Nov 13, 2023	J-GAAP
Apr - Sep, 2024 Guidance	123,400	10,500	10,300	6,500	132.0	30	Nov 5, 2024	J-GAAP
YoY	+14.9%	+49.9%	+0.7%	-6.5%	-6.5%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	208,859	5,514	5,141	2,201	44.7	60	May 15, 2023	J-GAAP
Mar, 2024	227,934	17,647	24,477	16,173	328.6	60	May 14, 2024	J-GAAP
Mar, 2025 Guidance	262,100	23,300	22,700	15,000	304.7	60	Nov 5, 2024	J-GAAP
YoY	+15.0%	+32.0%	-7.3%	-7.3%	-7.3%